Agenus to present botensilimab data in oral plenary session at the society of gynecologic oncology 2023 annual meeting on women's cancer

Lexington, mass., feb. 28, 2023 (globe newswire) -- agenus (nasdaq: agen), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced plans to present updated data on its lead program botensilimab (fc-enhanced anti-ctla-4), at the society of gynecologic oncology (sgo) 37th annual meeting on women's cancer, to be held march 25-28 in tampa, fl. updated data from an expansion cohort of the phase 1 study of botensilimab in combination with balstilimab (anti-pd-1) in patients with recurrent platinum refractory/resistant ovarian cancer will be presented at an oral plenary session on monday, march 27th at 9:18am et.
AGEN Ratings Summary
AGEN Quant Ranking